Cargando…

Exposure‐Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis—Analyses of Phase 2b Study to Support Selection of Phase 3 Doses

Upadacitinib is a selective Janus kinase 1 inhibitor that was recently approved for treatment of rheumatoid arthritis and is currently being evaluated for treatment of several other autoimmune diseases, including atopic dermatitis (AD). The relationships between upadacitinib plasma exposure and effi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohamed, Mohamed‐Eslam F., Gopalakrishnan, Sathej, Teixeira, Henrique D., Othman, Ahmed A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Exposure Response
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049015/ https://www.ncbi.nlm.nih.gov/pubmed/33156550 http://dx.doi.org/10.1002/jcph.1782

Ejemplares similares

Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients – Analyses of phase III clinical trials
por: Muensterman, Elena, et al.
Publicado: (2021)

Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
por: Luo, Man (Melody), et al.
Publicado: (2020)

Exposure–Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019)

Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials
por: Klünder, Ben, et al.
Publicado: (2017)

Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every‐4‐Week Dosing to Extended‐Interval Dosing
por: Chang, Ih, et al.
Publicado: (2020)

Exposure‐Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection
por: Ueno, Takayo, et al.
Publicado: (2018)

Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies
por: Ruiz‐Garcia, Ana, et al.
Publicado: (2020)

Exposure–Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit–Risk Assessment in Rheumatoid Arthritis
por: Nader, Ahmed, et al.
Publicado: (2019)

Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials
por: Klünder, Ben, et al.
Publicado: (2019)

Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure‐Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019)

Exposure–Response Analyses for Upadacitinib Efficacy and Safety in the Crohn's Disease CELEST Study and Bridging to the Extended‐Release Formulation
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019)

Exposure
Publicado: (2020)

Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2021)

Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: 2-Year Interim Results from the Phase 3 Rising Up Study
por: Katoh, Norito, et al.
Publicado: (2022)

Atopic Dermatitis and Ulcerative Colitis Successfully Treated with Upadacitinib
por: Grieco, Teresa, et al.
Publicado: (2023)

Acne Among Japanese Patients with Atopic Dermatitis Receiving Upadacitinib in the Phase 3 Rising Up Study
por: Hayashi, Nobukazu, et al.
Publicado: (2023)

Dose–response relationship between hand–arm vibration exposure and vibrotactile thresholds among roadworkers
por: Clemm, Thomas, et al.
Publicado: (2020)

Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended‐Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2018)

Exacerbation of human papillomavirus infection with initiation of upadacitinib for atopic dermatitis
por: Seale, Emily, et al.
Publicado: (2023)

Model‐Informed Dosing of Venetoclax in Healthy Subjects: An Exposure−Response Analysis
por: Dave, Nimita, et al.
Publicado: (2019)

Cross-national comparison of two general population job exposure matrices for physical work exposures
por: Evanoff, Bradley, et al.
Publicado: (2019)

The CONSTANCES job exposure matrix based on self-reported exposure to physical risk factors: development and evaluation
por: Evanoff, Bradley A, et al.
Publicado: (2019)

Job-exposure matrix for historical exposures to rubber dust, rubber fumes and n-Nitrosamines in the British rubber industry
por: Hidajat, Mira, et al.
Publicado: (2019)

The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2018)

Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication
por: Mohamed, Mohamed-Eslam F., et al.
Publicado: (2019)

Cross-shift study of exposure–response relationships between bioaerosol exposure and respiratory effects in the Norwegian grain and animal feed production industry
por: Straumfors, Anne, et al.
Publicado: (2016)

Exposure of hairdressers to ortho- and meta-toluidine in hair dyes
por: Johansson, Gabriella M, et al.
Publicado: (2015)

Occupational exposure to pesticides is associated with differential DNA methylation
por: van der Plaat, Diana A, et al.
Publicado: (2018)

Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019)

Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics
por: Trueman, Sheryl, et al.
Publicado: (2019)

Incident CTS in a large pooled cohort study: associations obtained by a Job Exposure Matrix versus associations obtained from observed exposures
por: Dale, Ann Marie, et al.
Publicado: (2018)

CAREX Canada: an enhanced model for assessing occupational carcinogen exposure
por: Peters, Cheryl E, et al.
Publicado: (2015)

Ambient air pollution exposure and chronic bronchitis in the Lifelines cohort
por: Doiron, Dany, et al.
Publicado: (2021)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
por: Nogueira, Miguel, et al.
Publicado: (2021)

Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults
por: De Greef, Axel, et al.
Publicado: (2023)

Atopic dermatitis treated with tralokinumab and upadacitinib combination therapy: A case report
por: Lansang, Rafael Paolo, et al.
Publicado: (2023)

Neglected exposure route: cobalt on skin and its associations with urinary cobalt levels
por: Kettelarij, Jolinde, et al.
Publicado: (2018)

Half-lives of PFOS, PFHxS and PFOA after end of exposure to contaminated drinking water
por: Li, Ying, et al.
Publicado: (2018)

Developing a company-specific job exposure matrix for the Asbest Chrysotile Cohort Study
por: Feletto, Eleonora, et al.
Publicado: (2022)

Fluorene exposure among PAH-exposed workers is associated with epigenetic markers related to lung cancer
por: Alhamdow, Ayman, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_obr9ib703udt0lfdlpu9sri8to